{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:42:36Z","timestamp":1783089756571,"version":"3.54.6"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173305"],"award-info":[{"award-number":["82173305"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study was to assess the impact of chemotherapy sequence on the prognosis of patients with gastric cancer (GC) undergoing gastrectomy and identify optimal chemotherapy timing along with potential candidates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>Data on patients who underwent gastrectomy were extracted from Surveillance, Epidemiology, and End Results database. Prognostic factors for overall survival (OS) were assessed using Kaplan-Meier and Cox regression analyses. Treatment strategies were categorized into neoadjuvant chemotherapy (NAC), adjuvant chemotherapy (AC), and perioperative chemotherapy (PC), with subsequent analyses of clinical outcomes. Stable inverse probability of treatment weighting (sIPTW) and subgroup analyses were conducted to evaluate the significance of chemotherapy timing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 4914 patients, 38.4% received NAC, 45% received AC, and 16.6% received PC. The 5-year OS rates for the entire cohort were 41.2%. Although no significant differences were observed between NAC and AC, PC exhibited a substantial improvement in OS compared to both. Multivariate analysis highlighted chemotherapy timing as a prognostic factor for OS. Even after sIPTW, PC still demonstrated significantly longer OS compared to NAC and AC, and this trend persisted across almost all subgroups. Even after patients underwent NAC and gastrectomy, AC remained essential. Notably, potential candidates exempt from AC were identified, including patients aged \u226565 years and those with tumor grades I-II.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Chemotherapy timing was an independent prognostic factor for resected GC. PC presented as a promising strategy, displaying superior OS compared to both NAC and AC. However, older individuals and those with well-differentiated tumors could be considered exempt from further AC after receiving NAC and gastrectomy. Further research is needed to validate these findings and optimize GC management.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf179","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:23:36Z","timestamp":1751408616000},"source":"Crossref","is-referenced-by-count":1,"title":["Timing and clinical significance of chemotherapy in patients with resected gastric adenocarcinoma: a population-based cohort study"],"prefix":"10.1093","volume":"30","author":[{"given":"Di","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwang","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]},{"name":"Institute of Marine Science and Technology, Shandong University , Qingdao, 266237 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaodi","family":"Nan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulun","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyuan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliang","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiao","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehui","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5868-4482","authenticated-orcid":false,"given":"Lian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University , Jinan, 250012 ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"2025072210413610700_CIT0001","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025072210413610700_CIT0002","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s10120-022-01317-6","article-title":"A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese Gastric Cancer Association nationwide registry (2001-2013)","volume":"25","author":"Kakeji","year":"2022","journal-title":"Gastric Cancer"},{"key":"2025072210413610700_CIT0003","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine","volume":"357","author":"Sakuramoto","year":"2007","journal-title":"N Engl J Med"},{"key":"2025072210413610700_CIT0004","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025072210413610700_CIT0005","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1200\/JCO.2014.58.3930","article-title":"Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses","volume":"33","author":"Park","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025072210413610700_CIT0006","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","article-title":"A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial(\u2606)","volume":"32","author":"Park","year":"2021","journal-title":"Ann Oncol"},{"key":"2025072210413610700_CIT0007","doi-asserted-by":"publisher","first-page":"108343","DOI":"10.1016\/j.ejso.2024.108343","article-title":"Impact of pCR after neoadjuvant chemotherapy and radical D2 dissection in locally advanced gastric cancers: Analysis of 1001 cases","volume":"50","author":"Bhandare","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"2025072210413610700_CIT0008","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"2025072210413610700_CIT0009","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","article-title":"Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial","volume":"22","author":"Zhang","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025072210413610700_CIT0010","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","article-title":"PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer","volume":"39","author":"Kang","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025072210413610700_CIT0011","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/jso.23009","article-title":"Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer","volume":"105","author":"Li","year":"2012","journal-title":"J Surg Oncol"},{"key":"2025072210413610700_CIT0012","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10120-024-01471-z","article-title":"Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial","volume":"27","author":"Jiang","year":"2024","journal-title":"Gastric Cancer"},{"key":"2025072210413610700_CIT0013","author":"National Comphrehensive Cancer Network","year":"2023","journal-title":"NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer"},{"key":"2025072210413610700_CIT0014","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s10120-019-00961-9","article-title":"Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset","volume":"22","author":"Nakanishi","year":"2019","journal-title":"Gastric Cancer"},{"key":"2025072210413610700_CIT0015","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/bjc.2013.86","article-title":"Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201)","volume":"108","author":"Kang","year":"2013","journal-title":"Br J Cancer"},{"key":"2025072210413610700_CIT0016","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1200\/JCO.18.01138","article-title":"Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial","volume":"37","author":"Yoshida","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025072210413610700_CIT0017","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s10120-021-01243-z","article-title":"Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study","volume":"25","author":"Kim","year":"2022","journal-title":"Gastric Cancer"},{"key":"2025072210413610700_CIT0018","doi-asserted-by":"publisher","first-page":"113370","DOI":"10.1016\/j.ejca.2023.113370","article-title":"Treatment of gastric adenocarcinoma: A rapidly evolving landscape","volume":"195","author":"Taieb","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025072210413610700_CIT0019","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s10120-019-00956-6","article-title":"Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study","volume":"22","author":"Mokadem","year":"2019","journal-title":"Gastric Cancer"},{"key":"2025072210413610700_CIT0020","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s11605-023-05641-9","article-title":"Systematic review and meta-analysis of the outcomes following neoadjuvant therapy in upfront resectable gastric cancers compared to surgery alone in phase III randomised controlled trials","volume":"27","author":"Lim Khai Shin","year":"2023","journal-title":"J Gastrointest Surg"},{"key":"2025072210413610700_CIT0021","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.3390\/ijms24054877","article-title":"Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing","volume":"24","author":"Lavacchi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025072210413610700_CIT0022","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial","volume":"17","author":"Fujitani","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025072210413610700_CIT0023","doi-asserted-by":"publisher","first-page":"104082","DOI":"10.1016\/j.critrevonc.2023.104082","article-title":"Perioperative chemotherapy versus adjuvant chemotherapy in patients with resectable gastric cancer: a systematic review with meta-analysis","volume":"198","author":"Wei","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025072210413610700_CIT0024","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.3390\/cancers15164114","article-title":"The present and future of neoadjuvant and adjuvant therapy for locally advanced gastric cancer","volume":"15","author":"Koerner","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025072210413610700_CIT0025","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"2025072210413610700_CIT0026","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"2025072210413610700_CIT0027","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/go.2023.9.supplement_1.30","article-title":"Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial","volume":"9","author":"Ryu","year":"2023","journal-title":"JCO"},{"key":"2025072210413610700_CIT0028","doi-asserted-by":"publisher","first-page":"S1254","DOI":"10.1016\/j.annonc.2023.10.079","article-title":"Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy: An updated analysis of RESOLVE trial","volume":"34","author":"Zhang ZL","year":"2023","journal-title":"Ann Oncol"},{"key":"2025072210413610700_CIT0029","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10120-020-01136-7","article-title":"Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial","volume":"24","author":"Iwasaki","year":"2021","journal-title":"Gastric Cancer"},{"key":"2025072210413610700_CIT0030","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-024-01536-7","article-title":"Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II\/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial","volume":"17","author":"Wang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2025072210413610700_CIT0031","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1200\/jco.2023.41.4_suppl.364","article-title":"PERSIST: A multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric\/gastroesophageal junction cancer (GC\/GEJC)","volume":"41","author":"Ding","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025072210413610700_CIT0032","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1200\/jco.2023.41.16_suppl.4001","article-title":"Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial","volume":"41","author":"Yuan","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025072210413610700_CIT0033","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, Phase II\/III DANTE\/IKF-s633 Trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025072210413610700_CIT0034","doi-asserted-by":"publisher","first-page":"S1315","DOI":"10.1016\/j.annonc.2023.10.074","article-title":"LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): Interim results of the global, phase III MATTERHORN study","volume":"34","author":"Janjigian","year":"2023","journal-title":"Ann Oncol"},{"key":"2025072210413610700_CIT0035","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41467-022-35431-x","article-title":"Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"2025072210413610700_CIT0036","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.7150\/jca.31755","article-title":"Changes in expression of multiple checkpoint molecules and infiltration of tumor immune cells after neoadjuvant chemotherapy in gastric cancer","volume":"10","author":"Yu","year":"2019","journal-title":"J Cancer"},{"key":"2025072210413610700_CIT0037","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41591-023-02721-w","article-title":"Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial","volume":"30","author":"Yuan","year":"2024","journal-title":"Nat Med"},{"key":"2025072210413610700_CIT0038","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.semcancer.2022.05.015","article-title":"Neoadjuvant immunotherapy in gastrointestinal cancers - The new standard of care","volume":"86","author":"Petricevic","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"2025072210413610700_CIT0039","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1016\/j.ejso.2019.03.040","article-title":"Poor compliance with perioperative chemotherapy for resectable gastric cancer and its impact on survival","volume":"45","author":"van Putten","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"2025072210413610700_CIT0040","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s10147-011-0349-5","article-title":"Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials","volume":"18","author":"Yano","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"2025072210413610700_CIT0041","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1349-7006.2010.01793.x","article-title":"Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients","volume":"102","author":"Chuah","year":"2011","journal-title":"Cancer Sci"},{"key":"2025072210413610700_CIT0042","doi-asserted-by":"publisher","first-page":"e2200420","DOI":"10.1200\/PO.22.00420","article-title":"Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers","volume":"6","author":"Huffman","year":"2022","journal-title":"JCO Precis Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf179\/63638873\/oyaf179.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf179\/63638873\/oyaf179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/7\/oyaf179\/63638873\/oyaf179.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T14:41:45Z","timestamp":1753195305000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf179\/8180721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf179","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"oyaf179"}}